Compare KraneShares CSI China Internet ETF (KWEB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Regeneron Pharmaceuticals Inc — how do they compare? KraneShares CSI China Internet ETF trades at $24.93 (market cap $4.37B), while Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 17.4× KraneShares CSI China Internet ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while KraneShares CSI China Internet ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| KWEB | REGN | |
|---|---|---|
Market Cap | $4.37B | $76.14B |
Volume | 13,393,361 | 500,239 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $852.03 |
52-Week Low | $23.63 | $557.73 |
Typical Hold Time | 57 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.93, up 2.47% today but maintains a bearish technical outlook with all 13 moving averages signaling sell. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent institutional activity shows mixed sentiment with Tidal Investments reducing its stake by 39.1% while HSBC increased its position by 27.7% in recent quarters.
The China internet ETF remains under pressure from geopolitical tensions and economic rebalancing concerns. While corporate profits surged 26% in Q2 2026, ongoing U.S.-China trade dynamics and potential export curbs create uncertainty. Technical indicators suggest continued bearish momentum with key support at $24.
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
